Protalix BioTherapeutics Profit Margin

As of the most recent data (March 2026), PLX shows a profit margin of 20.07%. That compares with 6.54% in the prior-year period — up 207.0% year over year. That is above the Healthcare sector average of 15.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PLX's profit margin is now 20.07% (was 6.54%) — a 207.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Protalix BioTherapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 15.58%. Protalix BioTherapeutics is at 20.07%, which is higher that average. That is roughly 28.8% above the sector mean. Use the comparison chart on this page to see how PLX stacks up against individual peers as well.

That compares with 6.54% in the prior-year period — up 207.0% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Protalix BioTherapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Protalix BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 20.07%) with ownership activity and broader fundamentals.